---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291176903.md"
description: "Palisade Bio shares are trading higher after FDA approval of its Investigational New Drug application for PALI-2108, which allows the company to start its Phase 2 ASCENTRA-UC trial in patients with ulcerative colitis."
datetime: "2026-06-29T17:28:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291176903.md)
  - [en](https://longbridge.com/en/news/291176903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291176903.md)
---

# 

Palisade Bio shares are trading higher after FDA approval of its Investigational New Drug application for PALI-2108, which allows the company to start its Phase 2 ASCENTRA-UC trial in patients with ulcerative colitis.

### Related Stocks

- [PALI.US](https://longbridge.com/en/quote/PALI.US.md)

## Related News & Research

- [Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2](https://longbridge.com/en/news/293653896.md)
- [Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trial](https://longbridge.com/en/news/291145871.md)
- [Insider Move: Palisade Bio Director Makes Bold New Stock Bet](https://longbridge.com/en/news/292141681.md)
- [Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by Analysts](https://longbridge.com/en/news/293182118.md)
- [Palisade Bio to meet investors at Leerink Partners Therapeutics Forum July 14-15](https://longbridge.com/en/news/292324391.md)